

High survivorship and significantly improved clinical outcomes with JOURNEY[®] II UK with OXINIUM[®] Technology for medial and lateral UKA

D'Amario F, Vitale U, De Dona F, Ruosi L, Cofone A, Loppini M. Evaluation of functional outcomes, survivorship and complications of hypoallergenic fixed-bearing medial and lateral unicompartmental knee arthroplasty: a minimum 2-year follow-up. *J Clin Med*. 2025;14(5):1748.

Available at: [Journal of Clinical Medicine](#)  

Key points

Patients undergoing UKA with JOURNEY II UK with OXINIUM Technology at 24 months had:



Overview

- Single centre, single non-developer surgeon, retrospective study of patients undergoing medial and lateral UKA with JOURNEY II UK in Italy
 - 257 patients undergoing surgery between December 2020 and December 2022 with ≥ 2 -year follow-up
- Forgotten Joint Score-12 (FJS-12) was collected at 12 and 24 months, and survivorship (defined as patients without re-surgery for any reason) and patient satisfaction were assessed at 24 months
- Mean age and BMI of patients was 67.5 years and 26.6kg/m², respectively
- The following outcomes were assessed pre-operatively and post-operatively at 12 and 24 months:
 - Knee Society Knee Score (KSKS)
 - Knee Society Function Score (KSFS)
 - Oxford Knee Score (OKS)
 - University of California, Los Angeles Activity Score (UCLA)
 - Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS)
 - SF-36 Mental Component Summary (MCS)

Results

- At 24 months follow-up, survivorship was 99.6% (256/257 patients had no re-operations for any reason) with JOURNEY II UK
 - One patient had a revision to TKA due to aseptic loosening of the medial tibial component 12 months post-operation
- Compared with pre-operative scores, multiple clinical and patient-reported outcomes were significantly improved at 12 months and 24 months (Table)
- FJS-12 significantly improved from 12 months to 24 months (81.64 vs 85.47; $p < 0.05$)
- Patient satisfaction scored highly at 24 months (9.2/10)

Table. Significant improvements in clinical and patient-reported outcomes versus pre-operative scores

Outcome	Pre-operative mean	12 months mean	24 months mean	p value
KSKS	44.53	86.17	89.31	<0.001
KSFS	53.12	87.78	90.44	<0.001
OKS	35.69	22.43	17.94	<0.001
UCLA	4.53	6.30	7.30	<0.001
SF-36 PCS	31.51	42.54	51.86	<0.001
SF-36 MCS	47.04	52.35	56.41	<0.001

Conclusions

At 24-month follow-up, UKA with JOURNEY II UK with OXINIUM Technology resulted in high survivorship and patient satisfaction with significantly improved clinical and patient-reported outcomes versus pre-operative scores.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.